VORANIGO
® is a once-daily pill for people with Grade 2 IDH‑mutant glioma, astrocytoma, or oligodendroglioma.
VORANIGO (40 mg tablets) is a prescription medicine used to treat adults and children 12 years of age and older with certain types of brain tumors called astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, following surgery. It is not known if VORANIGO is safe and effective in children under 12 years of age.
See Rob’s story
Rob shares his story about living with Grade 2 oligodendroglioma, staying positive, and moving forward with VORANIGO.
Watch nowVORANIGO in glioma
VORANIGO is a targeted treatment and is the first therapy in over 20 years for IDH-mutant glioma. Learn about mutations in glioma and how VORANIGO inhibits mutated IDH1 and IDH2 enzymes.
Learn moreVORANIGO results
The FDA approved VORANIGO based on the results of a clinical trial that showed that VORANIGO delayed disease progression in IDH-mutant astrocytoma and oligodendroglioma.
VORANIGO resultsOne pill, once daily
VORANIGO is a pill taken once daily around the same time each day. See more details about how to take VORANIGO.
See dosing